Provide your email for confirmation

Tell us a bit about yourself

country *

Please provide your email address

welcome to Rappler

Login

To share your thoughts

Don't have an account?

Login with email

Check your inbox

We just sent a link to your inbox. Click the link to continue signing in. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Use password?

Login with email

Reset password?

Please use the email you used to register and we will send you a link to reset your password

Check your inbox

We just sent a link to your inbox. Click the link to continue resetting your password. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Sign up

Ready to get started

Already have an account?

Sign up with email

By signing up you agree to Rappler’s Terms and Conditions and Privacy

Check your inbox

We just sent a link to your inbox. Click the link to continue registering. Can’t find it? Check your spam & junk mail.

Didn't get a link?

Join Rappler+

Join Move

How often would you like to pay?

Annual Subscription

Monthly Subscription

Your payment was interrupted

Exiting the registration flow at this point will mean you will loose your progress

Your payment didn’t go through

Exiting the registration flow at this point will mean you will loose your progress

welcome to Rappler+

welcome to Move

welcome to Move & Rappler+

Australia to continue AstraZeneca vaccination despite blood clotting case

Australia will continue its inoculation program with AstraZeneca PLC, health officials said on Saturday, April 3, after a blood clotting case raised concern about the safety of the vaccine.

A 44-year-old man was admitted to a Melbourne hospital with clotting, days after receiving the AstraZeneca vaccine, suffering serious thrombosis, a condition that prevents normal blood flow through the circulatory system.

The Therapeutic Goods Administration (TGA) regulator and a panel, the Australian Technical Advisory Group on Immunisation (ATAGI), met late Friday and early Saturday to discuss further advice on the AstraZeneca vaccine.

"We have not been advised at this time by ATAGI or the TGA to pause the rollout of the AstraZeneca vaccine in Australia," Australia's deputy chief medical officer, Michael Kidd, told a televised briefing Saturday afternoon.

Kidd said, however, that the blood clotting case is "likely" related to the vaccine.

"The risks of serious side effects remain very low, but safety is paramount and that is why TAGI and the TGA are continuing to do due diligence on this case," Kidd said, adding that further announcements would come next week.

On Thursday, Britain identified 30 cases of rare blood clot events following use of the vaccine. Several nations, including Canada, France, Germany and Spain, limited its use after similar reports.

Possible complications with the rollout of the AstraZeneca vaccine could further slow the already delayed inoculation drive in Australia.

Australia launched mass vaccinations for its 25 million people in February, with most expected to receive the University of Oxford/AstraZeneca vaccine, as 50 million doses are being produced domestically by CSL Ltd.

The country has had troubles, however, rolling out the program, missing a March target by about 3.3 million doses as states and the federal government bickered over the blame.

The troubles follow a year of significant success curbing the virus, with snap lockdowns, border closures and swift tracking limiting coronavirus infections to just under 29,300 infections, with 909 COVID-19 deaths.

On Saturday, Queensland state, the epicenter of the most recent small outbreak of the coronavirus, recorded one new infection, health officials said, but risks to the public were minimal as the victim had been in isolation for days.